Do Fetal Extravillous Trophoblasts Circulate in Maternal Blood Postpartum?

Acta Obstetricia et Gynecologica Scandinavica. April 2020

Looij A, Singh R, Hatt L, Ravn K, Jeppesen LD, Nicolaisen BH, Kølvraa M, Vogel I, Schelde P, Uldbjerg N

ABSTRACT

Introduction
Circulating fetal extravillous trophoblasts may offer a superior alternative to cell-free fetal DNA for
noninvasive prenatal testing. Cells of fetal origin are a pure source of fetal genome, hence, unlike
cell-free noninvasive prenatal test, fetal cell-based noninvasive prenatal test is not expected to be
affected by maternal DNA. However, circulating fetal cells from previous pregnancies may lead to
confounding results.

Material and methods
In order to study whether fetal trophoblast cells persist in maternal circulation postpartum, blood samples were collected from 11 women who had given birth to a boy, with blood sampling at 1-3 days (W0), 4-5 weeks (W4-5), around 8 weeks (W8), and around 12 weeks (W12) postpartum. The existence of fetal extravillous trophoblasts was verified either by X and Y chromosome  fluorescence in-situ hybridization analysis, or by short tandem repeat analysis. In order to exclude technological bias in isolating fetal cells, blood samples were also collected from 10 pregnant women in gestational age of 10-14 weeks, the optimal time frame for cell-based noninvasive prenatal test sampling. All the samples were processed according to protocols established by
ARCEDI Biotech for fetal extravillous trophoblasts enrichment and isolation.

Results
Fetal extravillous trophoblasts were found in all the 10 samples from pregnant women in  gestational age of 10-14 weeks. However, only four out of 11 blood samples taken from women, one to three days postpartum rendered fetal extravillous trophoblasts. And only two out of 11 samples rendered fetal extravillous trophoblasts at four weeks postpartum.

Conclusions
In this preliminary dataset on few pregnancies, none of the samples rendered any fetal cells at or
after eight weeks postpartum, showing that cell-based noninvasive prenatal testing based on fetal
extravillous trophoblasts is unlikely to be influenced by circulating cells from previous pregnancies.

READ MORE